Should We Use bDMARDs as an Induction Therapy in Early and Severe Rheumatoid Arthritis? Results at 5 years from the ERA UCLouvain Brussels Cohort

INTRODUCTION: This study sought to analyze the benefit of an early induction therapy with a biological disease-modifying anti-rheumatic drugs (bDMARD) during the first year of treatment with a 5-year follow-up in early rheumatoid arthritis (ERA). METHODS: We included ERA patients from the UCLouvain...

Descripción completa

Detalles Bibliográficos
Autores principales: Sapart, Emilie, Sokolova, Tatiana, de Montjoye, Stéphanie, Dierckx, Stéphanie, Nzeusseu, Adrien, Avramovska, Aleksandra, Meric de Bellefon, Laurent, Durez, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326217/
https://www.ncbi.nlm.nih.gov/pubmed/37183237
http://dx.doi.org/10.1007/s40744-023-00551-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326217/
https://www.ncbi.nlm.nih.gov/pubmed/37183237
http://dx.doi.org/10.1007/s40744-023-00551-3

Ejemplares similares